EP1617890B1 - Medical device with antimicrobial layer - Google Patents

Medical device with antimicrobial layer Download PDF

Info

Publication number
EP1617890B1
EP1617890B1 EP04760444A EP04760444A EP1617890B1 EP 1617890 B1 EP1617890 B1 EP 1617890B1 EP 04760444 A EP04760444 A EP 04760444A EP 04760444 A EP04760444 A EP 04760444A EP 1617890 B1 EP1617890 B1 EP 1617890B1
Authority
EP
European Patent Office
Prior art keywords
medical device
antimicrobial compound
wall
hydrophilic polymer
cuff
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04760444A
Other languages
German (de)
French (fr)
Other versions
EP1617890A2 (en
Inventor
Paul W. Martens
Robert L. Nieto
Robert Virag
Adin M. Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of EP1617890A2 publication Critical patent/EP1617890A2/en
Application granted granted Critical
Publication of EP1617890B1 publication Critical patent/EP1617890B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04Tracheal tubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04Tracheal tubes
    • A61M16/0434Cuffs
    • A61M16/0443Special cuff-wall materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2002/046Tracheae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104Silver, e.g. silver sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/10Tube connectors; Tube couplings
    • A61M39/16Tube connectors; Tube couplings having provision for disinfection or sterilisation
    • A61M39/162Tube connectors; Tube couplings having provision for disinfection or sterilisation with antiseptic agent incorporated within the connector

Definitions

  • the present invention relates to medical devices, and more particularly, to a method of adding an antimicrobial function to a medical device.
  • a process for applying a lubricious coating to a surface of a substrate is known from US 5620738 .
  • VAP Ventilator Associated Pneumonia
  • VAP infections Prolongation of hospitalization, ventilation, and management of VAP infections may add up to seven days in additional patient care and over $5,000 in incremental treatment costs per patient.
  • the costs associated with VAP may be in excess of $1.5 billion per year. It would be desirable if costs associated with the prevention and intervention of VAP could be reduced.
  • VAP may be associated with the long-term use of invasive positive pressure medical devices such as mechanical ventilators or tracheal tubes.
  • Medical devices may be suction catheters, gastric feeding tubes, esophageal obturators, esophageal balloon catheters, oral and nasal airways, bronchoscopes, breathing circuits, filters, heat and moisture exchanges, or humidifiers.
  • Tracheal tubes may be airway management devices such as endotracheal (ET) tubes, tracheostomy tubes, or transtracheal tubes.
  • ET endotracheal
  • Airway management devices such as ET tubes may be associated with VAP because they may provide a substrate upon which bacterial colonization can occur.
  • Bacteria for colonization may come from inhaled aerosols and nasal, oropharyngeal, and gastric secretions. Bacteria for colonization may also result from the formation of microbial adhesions or biofilms on the surfaces of contaminated medical devices. Colonization, in turn, may lead to microaspiration of pulmonary pathogens and related lung infection.
  • bacteria 18 for colonization may "flow" down an ET tube 10 from the mouth along with oral, nasal or gastric secretions. Such bacteria may flow to the area immediately before the cuff 4 and pool there, eventually becoming sessile on the outer surface of the ET tube. Microorganisms may adhere to an abiotic surface and allow complex biofilms to form. The complex biofilm may protect the microorganisms against antibiotic action.
  • the accretion of antibiotic-resistant biofilms may form a reservoir of infecting microorganisms which may then migrate from the ET outer surface past the protective cuff and contaminate the trachea and lungs.
  • Lung secretions containing microorganisms, blood, mucous, and cellular debris may colonize on the tip and inner lumen of the ET to form biofilms of antibiotic-resistant microorganisms.
  • Such interluminal biofilms may occlude the breathing tube or migrate back into the lungs to cause further infection.
  • the process of removing these biofilms and secretions with conventional suction catheters may lead to the aspiration of fragments of biofilms or infected aerosols.
  • Contaminated suction catheters, feeding tubes, ventilator tubing and breathing circuits, or filters, heat and moisture exchangers, nebulizers, heated humidifiers, or other related breathing tubes or devices may be sources of microorganism contamination and thus may contribute to biofilm formation.
  • One method of mitigating colonization of the tube surface by bacteria is by suctioning. Suctioning of subglottic secretions that may collect above the ET cuff may reduce the likelihood of aspiration. Routine suctioning of subglottic secretions may be associated with significant reduction of VAP.
  • the Mallinckrodt Hi-Lo EvacTM tracheal tube is an example of an ET tube with an integral subglottic suctioning apparatus.
  • Another method of mitigating colonization of the tube surface by bacteria is by administration of large doses of antibiotics.
  • Administering large doses of antibiotics may promote the development of more disease resistant bacteriotypes and is thus undesirable.
  • the present invention relates to a medical device according to claim 1, and a method for making the medical device according to claim 17. It is an object of the present invention to reduce the incidence of VAP. This object can be achieved by the features of the independent claims and further enhancements are characterized in the dependent claims.
  • a medical device in a first embodiment, includes a conduit for a fluid which comprises a wall having an outer surface, the wall comprising a hydrophobic polymer, with an outer layer disposed on the outer surface, the outer layer comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein, the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, and wherein the wall and the outer layer are formed by extrusion.
  • a method of making a medical device includes the actions of providing a hydrophobic polymer, extruding the hydrophobic polymer to form a wall, producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, mixing the antimicrobial compound and a hydrophilic polymer, and extruding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
  • a system for making a medical device includes means for providing a hydrophobic polymer, means for extruding the hydrophobic polymer to form a wall, means for producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, means for mixing the antimicrobial compound and a hydrophilic polymer, and means for extruding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
  • a medical device in a fourth embodiment, includes a conduit for a fluid which comprises a wall having an outer surface, the wall comprising a hydrophobic polymer, with an outer layer disposed on the outer surface, the outer layer comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein, the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, and wherein the wall and the outer layer are formed by molding.
  • a method of making a medical device includes the actions of providing a hydrophobic polymer, molding the hydrophobic polymer to form a wall, producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, mixing the antimicrobial compound and a hydrophilic polymer, and molding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
  • Medical devices are devices which maybe used around or inserted into a living body.
  • One such medical device may be a tube such as an ET tube.
  • an ET tube is used in the following examples, the invention is not limited to ET tubes.
  • the invention may apply in various embodiments to other types of medical devices, such as tubes, catheters, stents, feeding tubes, breathing circuits, intravenous tubes, breathing tubes, circuits, and related airway accessories such as connectors, adapters, filters, humidifiers, nebulizers, and prosthetics as well.
  • Microbes may attach themselves to a surface before beginning colonization of the surface and the formation of biofilms.
  • the colonization of a surface by microbes may require the microbes to become sessile on the surface before attaching themselves to the surface. Preventing the microbes from becoming sessile may thus inhibit the colonization of a surface by microbes.
  • a biofilm may be described, in general, as a colony cooperative.
  • a biofilm may furthermore be of mixed species with a high degree of specialization or order among individual members of the biofilm.
  • normally inactive or quiet genes of these organisms may up-regulate, i.e . turn on, while the organisms settle on a surface, but prior to building the biofilm structure. Up-regulated organisms may become more adaptable to the colony way of life and may also become excessively virulent.
  • VAP may be produced by simple planktonic (free-floating) single cell microbes that may come from leakage around the cuff, or air entering from the tube lumen. Bacteria may become sessile and also resistant to antibiotics by accretion of a protective glycocalyx coating that becomes a biofilm over time. This biofilm may then change its texture, becoming smooth, thus adding further to its defense against antibiotics. Polyvinyl chloride (PVC) may, in some cases, contribute to the formation of such biofilms.
  • PVC Polyvinyl chloride
  • Microbes may be more likely to become sessile on hydrophobic surfaces such as, e.g ., those of polyethylene (PE), polypropylene (PP), silicone rubber such as polydimethylsiloxane (PDMS), and PVC.
  • Hydrophobic surfaces reject water.
  • Hydrophilic surfaces in contrast, which are characterized by an affinity for water, may inhibit microbes from attaching themselves to the surface, and consequently inhibit the formation of biofilms as well.
  • Friction between a medical device and surrounding tissue may cause irritation in the surrounding tissues such as vocal cords. Such friction may make it more difficult to insert a medical device in the first place- Such friction may also produce trauma to the surrounding tissues. It would be desirable for the surface of a medical device to have lower surface friction, so that it slid across surrounding tissues more easily.
  • Biofilms may adhere to surfaces of medical devices, resulting in a buildup of dried secretions. It would be desirable for a medical device to have a slippery surface so that biofilms may be less likely to adhere to the surface of the medical device. It would be further desirable for a medical device to have a slippery surface so that biofilms that did build up might be easier to remove by suctioning techniques, so less frequent suctioning might be required.
  • a medical device such as an ET tube may have a cuff.
  • a cuff may form a seal around the tube to block secretions that may otherwise be aspirated. It would be desirable for such a cuff to swell in thickness upon absorbing moisture from the surrounding tissues. It would further be desirable is such a swelling resulted in an ability to seal at a lower pressure, such as a lower contact pressure between the cuff and the surrounding tissues.
  • Medical devices, and in particular ET tubes are often formed of hydrophobic materials such as PVC. Microbes may be inhibited from attaching themselves to a hydrophobic surface by applying a hydrophilic layer over the hydrophobic surface.
  • a medical device may be formed of, e.g . a hydrophobic material coated with a hydrophilic material to give it a hydrophilic surface.
  • the hydrophilic coating may be, e.g . a polyurethane (PU), such as medical grade hydrophilic thermoplastic polyurethane.
  • Hydrophilic coatings may be applied by a coating operation.
  • a medical device such as an ET tube, may promote respiration. It would be desirable if the carbon dioxide (CO 2 ) content of respiration could be determined, so as to determine whether the intubation is proper. It would further be desirable if a hydrophilic surface of a medical device were injected with a chemical, such as an acid-base color dye, to indicate CO 2 concentration.
  • CO 2 carbon dioxide
  • Some elements may have a deleterious effect on microbes. Some of these metals may be oligodynamic, in that they have an effect in small quantities only. Some metals may kill microbes by destroying their cell walls or by interfering with the metabolic functions of the cells. These metals may thus have antimicrobial or antiseptic properties. Some examples of such metals are copper, silver, or gold. Silver or silver ions (Ag + ), for example, may be adsorbed on the bacterial cell surface as an RSAg complex-The RSAg complex may immobilize the respiratory activity of the cell and eventually kill the cell.
  • the hydrophilic layer may therefore further contain a metal such as copper, silver, or gold in a metal bearing material.
  • the metal may be elemental silver, powdered silver, silver ions (Ag + ), or a silver bearing material like silver oxide (AgO).
  • the hydrophilic layer may thus be an antimicrobial (AM) layer. In this way the colonization-inhibiting properties of the hydrophilic surface can be reinforced by antimicrobial properties.
  • the silver bearing material may be a phosphorus-based glass material that dissolves in water at a rate that may be a function of its particular formulation.
  • the glass may also contain trace amounts of other elements, such as calcium oxide (CaO).
  • the rate at which silver is released may further be a function of the rate at which the phosphorus-based glass material dissolves in water.
  • the silver, or the phosphorus-based glass material, or both may be powdered.
  • the hydrophilic layer may be wetted with water prior to use.
  • the hydrophilic layer may also attract and absorb water available in the host during use. The absorbed water may then dissolve the silver bearing phosphorus-based glass material and release the silver into the surroundings of the medical device.
  • the rate at which the silver bearing phosphorus-based glass material dissolves in water may in turn be a function of the amount of water available to dissolve it.
  • the release of silver over time which is defined as the elution rate and is measured in ⁇ -grams/cm 2 /day, may thus be tailored to the specific needs of the application by specifying the formulation of the phosphorus-based glass material.
  • the silver bearing material may be made up of about 5-10 % by weight, e.g . about 7.5 % phosphorus-based glass by weight. Such a material is available from Giltech Limited, 12 North Harbour Industrial Estate, Ayr, Scotland, Great Britain KA8 8BN.
  • the elution rate should be up to about 0.01 ⁇ -grams/cm 2 /day. In another embodiment, the elution rate should be between about 0.01 and 1.0 ⁇ -grams/cm 2 /day. In a preferred embodiment, the elution rate should be, e.g . about 0.4 ⁇ -grams/cm 2 /day.
  • bioactive pharmaceutical agents such as a bronchodilator, an anti-inflammatory agent, or a local anesthetic may be substantially dispersed in a phosphorus-based glass material within a hydrophilic layer.
  • bioactive pharmaceutical agents may be delivered to and absorbed by adjacent tissues in substantially the same manner as silver. Regulation and control of dosage, elution rate, and thickness in substantially the same manner as silver may also provide a beneficial pharmacologic or therapeutic action.
  • a hydrophilic coating may be applied to the surface of a medical device by, e.g . dipping, spraying, washing, or painting the hydrophilic coating on the surface. Since the volume of a coating is proportional to the thickness of the coating, however, a hydrophilic surface formed in one of these ways may have only a small volume within which silver is retained. Furthermore, if dipping, spraying, washing, or painting formed the hydrophilic coating, the silver may be present only on the surface of the coating.
  • the hydrophilic coating may have a limited capacity to hold silver prior to delivery. Furthermore, since the silver may only reside on the surface of the hydrophilic coating, the silver may wash off prematurely, early in the use of the medical device, leaving less silver to prevent future bacteria from becoming sessile and colonizing the surface of the tube.
  • hydrophilic layer were extruded or molded along with the medical device, since controlling the thickness of the extrusion or mold could then optimize the volume of the hydrophilic layer.
  • a medical device may be formed by extruding a wall of hydrophobic material along with one or more layers of an AM material.
  • a medical device may be formed by molding a wall of hydrophobic material along with one or more layers of an AM material.
  • Standard PVC material may form the wall of the medical device, along with one or more layers of an AM material.
  • the AM layer may be formed on an inner or an outer surface of the medical device wall.
  • the AM layer may be comprised of, e.g . polyurethane, such as a medical grade hydrophilic thermoplastic polyurethane into which has been substantially dispersed a silver bearing phosphorus-based glass material.
  • the AM layer may be within a range of about 0.002 mm - 2.5 mm in thickness, or about 0.13 mm in thickness. In another embodiment, the AM layer may be within a range of about 0.002 mm - 2.5 mm in thickness. In a third embodiment, the AM layer may be up to about 6.35 mm in thickness. In one embodiment, substantially similar materials may form both the inner and outer surfaces of the tube.
  • an inner or an outer AM layer may be simultaneously extruded with the medical device wall in a process commonly known as “co-extrusion”.
  • both an inner and an outer AM layer may be extruded simultaneously with the medical device wall in a process sometimes referred to as "tri-extrusion.”
  • Applying an AM layer to the surface of a medical device may reduce the incidence of VAR There may also be a production cost savings to be gained by extruding an AM layer on a medical device over a conventional coating process.
  • an AM layer is also applied to the cuff portion of the medical device.
  • only the outer surface of the cuff will have an AM layer since only the outer surface of the cuff is exposed to the patient.
  • An AM layer may be applied to the outer surface of the cuff portion of the medical device by, e.g . co-extruding the AM layer with the wall of the cuff.
  • the cuff wall may subsequently be expanded to form a thin-walled cuff device.
  • the cuffwall may be expanded by, e.g . a process such as extrusion blow molding.
  • a core or mandrel of the extruder has apertures to admit a gas such as pressurized air or an inert gas like nitrogen, into the medical device in the neighborhood of the cuff.
  • a mold clamps the medical device around the mandrel.
  • gas is admitted to the cuff area through the mandrel the cuff expands against the mold.
  • the cuff wall may be expanded in a second discrete expansion process following an extrusion or molding process, such as with a shuttle blowmolding process.
  • Medical device 100 may be a catheter, a stent, a feeding tube, an intravenous tube, an ET tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic, in various embodiments.
  • Medical device 100 may have a conduit 102 for a fluid and an inflatable cuff 104 disposed at a first end 114 of conduit 102.
  • the fluid may be a gas, an aerosol, a suspension, a vapor, or droplets of liquid dispersed in a gas.
  • a lumen 116 may be disposed alongside conduit 102 to inflate cuff 104.
  • a wall 112 of conduit 102 is made of a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound.
  • a wall 412 of conduit 102 is made of a hydrophobic polymer with an outer layer 406 composed of a hydrophilic polymer and an antimicrobial compound disposed on an outer surface 408 of wall 412.
  • An inner layer 404 composed of a hydrophilic polymer and an antimicrobial compound may further be disposed on an inner surface 410 of wall 412.
  • Outer surface 408 may also be an outer surface of cuff 104.
  • wall 412 is a hydrophobic compound containing a hydrophilic polymer and an antimicrobial compound.
  • a hydrophilic polymer and an antimicrobial compound are substantially dispersed, i.e . mixed with a hydrophobic compound forming wall 412 of conduit 102.
  • hydrophilic polymer and antimicrobial compound are substantially dispersed within cuff 104, with e.g . a hydrophobic compound forming cuff 104.
  • a method of making a medical device 100 comprises the actions of providing a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound, combining the hydrophilic polymer and the antimicrobial compound, forming the hydrophobic polymer into a wall 412 of a conduit 102, and substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound as an outer layer 406 on a outer surface 408 of conduit 102.
  • the method further includes forming the hydrophobic polymer into a cuff 104 on an end of conduit 102, and substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound on a surface of cuff 104.
  • the method further includes substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound as an inner layer 404 on an inner surface 410 of conduit 102 while wall 412 and outer layer 406 are being extruded.
  • a resulting thickness of the hydrophilic polymer and the antimicrobial compound layer 404 is controlled by the extruder. In an alternative embodiment, extruding the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound together forms a wall 412 of conduit 102.
  • a wall 412 of conduit 102 may be extruded from a hydrophobic compound while an inner layer 404 is extruded in a first predetermined formulation of a hydrophilic polymer and an antimicrobial compound on an inner surface 410 of conduit 102.
  • a wall 412 of conduit 102 may be extruded from a hydrophobic compound while an outer layer 406 is extruded in a second predetermined formulation of a hydrophilic polymer and an antimicrobial compound on an outer surface 408 of conduit.
  • an outer layer 406 composed of a hydrophilic polymer and the antimicrobial compound in a second predetermined Formulation may be, e.g . molded on outer surface 408 of conduit 102.
  • the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be, e.g . compounded together and extruded to form a wall 412 of conduit 102.
  • the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be, e.g . compounded together and extruded to form a wall 114 of cuff 104.
  • the hydrophilic polymer and the antimicrobial compound may be, e.g . molded on an outer surface of cuff 104.
  • the hydrophilic polymer and the antimicrobial compound may be, e.g . extruded on an outer surface of cuff 104.
  • cuff 104 may be, e.g . formed by extruding the hydrophobic polymer, hydrophilic polymer and antimicrobial compound into a cuff 104, and expanding cuff 104.
  • a system for making a medical device 100 includes means for providing a hydrophobic polymer, means for extruding the hydrophobic polymer to form a wall 412, means for producing an antimicrobial compound comprising a predetermined amount ofphosphorus-based glass having a quantity of silver substantially dispersed therein, means for mixing the antimicrobial compound and a hydrophilic polymer, and means for extruding an outer layer 406 of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface 408 of the wall 412.
  • conduit 102 is formed by molding the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound in a mold.
  • Either the inner or the outer layers 404, 406, or both, may be molded in a mold with the wall 412.
  • the molding process may be overmolding, insert molding, blow-molding, laminate blow-molding, gas assisted molding, thermoplastic molding, injection molding, or compression molding.
  • a wall 412 may be formed into a tube covered by either an inner or the outer layers 404, 406 and inserted in a mold.
  • the tube maybe be heated in order to promote conformance to the shape of the mold.
  • a fluid such as pressurized air may be pumped into the tube so that the tube is forced or expanded against an inner surface of the mold.
  • a thickness of layers 404 or 406 may be controlled by a clearance between wall 412 and an inner surface of the mold.
  • a wall 412 and either an inner or outer antimicrobial compound layers 404 and 406 may be forced into a mold cavity to form the medical device.
  • a wall 412 made of hydrophobic polymer is placed in a mold and the hydrophilic polymer and the antimicrobial compound layers 404 and 406 are molded around it.
  • Fig. 3 is shown an extruder 300 for use with an embodiment of the invention.
  • Fig. 3 may include a main extruder 302 to extrude hydrophobic polymer for the wall 412, a satellite extruder 304 for the AM material, and a satellite extruder 306 for a radio-opaque material.
  • Satellite extruder 304 may feed matching gear pumps 308 to split the AM material into separate layers, one of which may be an inner layer 404 and the other an outer layer 406.
  • a head 310 collects the material streams from the individual satellite extruders, combines them with the flow of material for wall 412 and extrudes them into a medical device 100.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

A medical device includes a conduit for a fluid. The conduit has a wall formed of a hydrophobic polymer with a hydrophilic polymer layer extruded over it, and an antimicrobial substantially dispersed within the hydrophilic polymer. The antimicrobial compound may be a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal such as silver substantially dispersed therein. The medical device may be an endotracheal tube made by providing a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound, forming the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound into a conduit, and forming a cuff on an end of the conduit.

Description

    BACKGROUND OF THE INVENTION Field of the Invention:
  • The present invention relates to medical devices, and more particularly, to a method of adding an antimicrobial function to a medical device. A process for applying a lubricious coating to a surface of a substrate is known from US 5620738 .
  • Description of the Related Art:
  • Ventilator-associated pneumonia may be a cause of morbidity in critically ill patients. Approximately 250,000 cases of Ventilator Associated Pneumonia (VAP) are a reported each year. The mortality associated with VAP is approximately 23,000 patients annually. (Engelmann, J. et. al.: Ventilator-Associated Pneumonia, Seminars in Infection Control, Vol. 1 No. 2 2001).
  • Prolongation of hospitalization, ventilation, and management of VAP infections may add up to seven days in additional patient care and over $5,000 in incremental treatment costs per patient. The costs associated with VAP may be in excess of $1.5 billion per year. It would be desirable if costs associated with the prevention and intervention of VAP could be reduced.
  • VAP may be associated with the long-term use of invasive positive pressure medical devices such as mechanical ventilators or tracheal tubes. Medical devices may be suction catheters, gastric feeding tubes, esophageal obturators, esophageal balloon catheters, oral and nasal airways, bronchoscopes, breathing circuits, filters, heat and moisture exchanges, or humidifiers. Tracheal tubes may be airway management devices such as endotracheal (ET) tubes, tracheostomy tubes, or transtracheal tubes.
  • Airway management devices such as ET tubes may be associated with VAP because they may provide a substrate upon which bacterial colonization can occur. Bacteria for colonization may come from inhaled aerosols and nasal, oropharyngeal, and gastric secretions. Bacteria for colonization may also result from the formation of microbial adhesions or biofilms on the surfaces of contaminated medical devices. Colonization, in turn, may lead to microaspiration of pulmonary pathogens and related lung infection.
  • As shown in Fig. 1, bacteria 18 for colonization may "flow" down an ET tube 10 from the mouth along with oral, nasal or gastric secretions. Such bacteria may flow to the area immediately before the cuff 4 and pool there, eventually becoming sessile on the outer surface of the ET tube. Microorganisms may adhere to an abiotic surface and allow complex biofilms to form. The complex biofilm may protect the microorganisms against antibiotic action.
  • The accretion of antibiotic-resistant biofilms may form a reservoir of infecting microorganisms which may then migrate from the ET outer surface past the protective cuff and contaminate the trachea and lungs. Lung secretions containing microorganisms, blood, mucous, and cellular debris may colonize on the tip and inner lumen of the ET to form biofilms of antibiotic-resistant microorganisms. Such interluminal biofilms may occlude the breathing tube or migrate back into the lungs to cause further infection.
  • The process of removing these biofilms and secretions with conventional suction catheters may lead to the aspiration of fragments of biofilms or infected aerosols. Contaminated suction catheters, feeding tubes, ventilator tubing and breathing circuits, or filters, heat and moisture exchangers, nebulizers, heated humidifiers, or other related breathing tubes or devices may be sources of microorganism contamination and thus may contribute to biofilm formation.
  • One method of mitigating colonization of the tube surface by bacteria is by suctioning. Suctioning of subglottic secretions that may collect above the ET cuff may reduce the likelihood of aspiration. Routine suctioning of subglottic secretions may be associated with significant reduction of VAP. The Mallinckrodt Hi-Lo Evac™ tracheal tube is an example of an ET tube with an integral subglottic suctioning apparatus.
  • Suctioning, aspirating, or draining subglottic secretions, however, requires the frequent intervention of a clinician in order to be effective. It would be desirable if the incidence of VAP could be reduced without extensive reliance on suctioning. It would be desirable if the incidence of VAP could be reduced without requiring additional activities on the part of the clinician in order to be effective.
  • Another method of mitigating colonization of the tube surface by bacteria is by administration of large doses of antibiotics. Administering large doses of antibiotics, however, may promote the development of more disease resistant bacteriotypes and is thus undesirable.
  • SUMMARY
  • The present invention relates to a medical device according to claim 1, and a method for making the medical device according to claim 17. It is an object of the present invention to reduce the incidence of VAP. This object can be achieved by the features of the independent claims and further enhancements are characterized in the dependent claims. In a first embodiment, a medical device includes a conduit for a fluid which comprises a wall having an outer surface, the wall comprising a hydrophobic polymer, with an outer layer disposed on the outer surface, the outer layer comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein, the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, and wherein the wall and the outer layer are formed by extrusion.
  • In a second embodiment, a method of making a medical device includes the actions of providing a hydrophobic polymer, extruding the hydrophobic polymer to form a wall, producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, mixing the antimicrobial compound and a hydrophilic polymer, and extruding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
  • A system for making a medical device includes means for providing a hydrophobic polymer, means for extruding the hydrophobic polymer to form a wall, means for producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, means for mixing the antimicrobial compound and a hydrophilic polymer, and means for extruding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
  • In a fourth embodiment, a medical device includes a conduit for a fluid which comprises a wall having an outer surface, the wall comprising a hydrophobic polymer, with an outer layer disposed on the outer surface, the outer layer comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein, the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, and wherein the wall and the outer layer are formed by molding.
  • In a fifth embodiment, a method of making a medical device includes the actions of providing a hydrophobic polymer, molding the hydrophobic polymer to form a wall, producing an antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein, mixing the antimicrobial compound and a hydrophilic polymer, and molding a layer of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface of the wall.
  • BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
    • Fig. 1 shows a medical device in situ in a trachea;
    • Fig. 2 shows a plan view of a medical device according to an embodiment of the invention;
    • Fig. 3 shows a schematic of an extruder for use with an embodiment of the invention; and
    • Fig. 4 shows a section of a medical device according to the embodiment of Fig. 2.
    DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Medical devices are devices which maybe used around or inserted into a living body. One such medical device may be a tube such as an ET tube. Although an ET tube is used in the following examples, the invention is not limited to ET tubes. The invention may apply in various embodiments to other types of medical devices, such as tubes, catheters, stents, feeding tubes, breathing circuits, intravenous tubes, breathing tubes, circuits, and related airway accessories such as connectors, adapters, filters, humidifiers, nebulizers, and prosthetics as well.
  • Microbes may attach themselves to a surface before beginning colonization of the surface and the formation of biofilms. The colonization of a surface by microbes may require the microbes to become sessile on the surface before attaching themselves to the surface. Preventing the microbes from becoming sessile may thus inhibit the colonization of a surface by microbes.
  • A biofilm may be described, in general, as a colony cooperative. A biofilm may furthermore be of mixed species with a high degree of specialization or order among individual members of the biofilm. Additionally, normally inactive or quiet genes of these organisms may up-regulate, i.e. turn on, while the organisms settle on a surface, but prior to building the biofilm structure. Up-regulated organisms may become more adaptable to the colony way of life and may also become excessively virulent.
  • Particles of biofilm may fall into the lungs during treatment. These particles may produce VAP. VAP may also be produced by simple planktonic (free-floating) single cell microbes that may come from leakage around the cuff, or air entering from the tube lumen. Bacteria may become sessile and also resistant to antibiotics by accretion of a protective glycocalyx coating that becomes a biofilm over time. This biofilm may then change its texture, becoming smooth, thus adding further to its defense against antibiotics. Polyvinyl chloride (PVC) may, in some cases, contribute to the formation of such biofilms.
  • Microbes may be more likely to become sessile on hydrophobic surfaces such as, e.g., those of polyethylene (PE), polypropylene (PP), silicone rubber such as polydimethylsiloxane (PDMS), and PVC. Hydrophobic surfaces reject water. Hydrophilic surfaces, in contrast, which are characterized by an affinity for water, may inhibit microbes from attaching themselves to the surface, and consequently inhibit the formation of biofilms as well.
  • Friction between a medical device and surrounding tissue may cause irritation in the surrounding tissues such as vocal cords. Such friction may make it more difficult to insert a medical device in the first place- Such friction may also produce trauma to the surrounding tissues. It would be desirable for the surface of a medical device to have lower surface friction, so that it slid across surrounding tissues more easily.
  • Biofilms may adhere to surfaces of medical devices, resulting in a buildup of dried secretions. It would be desirable for a medical device to have a slippery surface so that biofilms may be less likely to adhere to the surface of the medical device. It would be further desirable for a medical device to have a slippery surface so that biofilms that did build up might be easier to remove by suctioning techniques, so less frequent suctioning might be required.
  • A medical device such as an ET tube may have a cuff. Such a cuff may form a seal around the tube to block secretions that may otherwise be aspirated. It would be desirable for such a cuff to swell in thickness upon absorbing moisture from the surrounding tissues. It would further be desirable is such a swelling resulted in an ability to seal at a lower pressure, such as a lower contact pressure between the cuff and the surrounding tissues.
  • Successive concentrations and rarefactions of moisture may occur across a medical device during intubation. It would be desirable if a surface of a medical device could transport moisture across such concentration gradients by, for example, osmosis. It would further be desirable if a hydrophilic layer on an inner diameter of a tracheal tube could condense and absorb moisture from exhaled gases in a cooler region of the tube and re-evaporate the warmed moisture to drier or cooler inhalation gases.
  • Medical devices, and in particular ET tubes are often formed of hydrophobic materials such as PVC. Microbes may be inhibited from attaching themselves to a hydrophobic surface by applying a hydrophilic layer over the hydrophobic surface. A medical device may be formed of, e.g. a hydrophobic material coated with a hydrophilic material to give it a hydrophilic surface. The hydrophilic coating may be, e.g. a polyurethane (PU), such as medical grade hydrophilic thermoplastic polyurethane. Hydrophilic coatings may be applied by a coating operation.
  • A medical device, such as an ET tube, may promote respiration. It would be desirable if the carbon dioxide (CO2) content of respiration could be determined, so as to determine whether the intubation is proper. It would further be desirable if a hydrophilic surface of a medical device were injected with a chemical, such as an acid-base color dye, to indicate CO2 concentration.
  • Destroying the microbes before they have a chance to become sessile and colonize the surface of the medical device could mitigate the conditions promoting colonization. It would further be desirable for the incidence of VAP to be reduced without extensive reliance on large doses of antibiotics.
  • Some elements, such as some metals, may have a deleterious effect on microbes. Some of these metals may be oligodynamic, in that they have an effect in small quantities only. Some metals may kill microbes by destroying their cell walls or by interfering with the metabolic functions of the cells. These metals may thus have antimicrobial or antiseptic properties. Some examples of such metals are copper, silver, or gold. Silver or silver ions (Ag+), for example, may be adsorbed on the bacterial cell surface as an RSAg complex-The RSAg complex may immobilize the respiratory activity of the cell and eventually kill the cell.
  • The hydrophilic layer may therefore further contain a metal such as copper, silver, or gold in a metal bearing material. In several exemplary embodiments, the metal may be elemental silver, powdered silver, silver ions (Ag+), or a silver bearing material like silver oxide (AgO). The hydrophilic layer may thus be an antimicrobial (AM) layer. In this way the colonization-inhibiting properties of the hydrophilic surface can be reinforced by antimicrobial properties.
  • It may be desirable for the silver to be released over time, while the medical device is in use. In one embodiment, therefore, the silver bearing material may be a phosphorus-based glass material that dissolves in water at a rate that may be a function of its particular formulation. The glass may also contain trace amounts of other elements, such as calcium oxide (CaO). The rate at which silver is released may further be a function of the rate at which the phosphorus-based glass material dissolves in water. The silver, or the phosphorus-based glass material, or both may be powdered.
  • The hydrophilic layer may be wetted with water prior to use. The hydrophilic layer may also attract and absorb water available in the host during use. The absorbed water may then dissolve the silver bearing phosphorus-based glass material and release the silver into the surroundings of the medical device. The rate at which the silver bearing phosphorus-based glass material dissolves in water may in turn be a function of the amount of water available to dissolve it.
  • The release of silver over time, which is defined as the elution rate and is measured in µ-grams/cm2/day, may thus be tailored to the specific needs of the application by specifying the formulation of the phosphorus-based glass material. In one embodiment, the silver bearing material may be made up of about 5-10 % by weight, e.g. about 7.5 % phosphorus-based glass by weight. Such a material is available from Giltech Limited, 12 North Harbour Industrial Estate, Ayr, Scotland, Great Britain KA8 8BN.
  • In one embodiment, the elution rate should be up to about 0.01 µ-grams/cm2/day. In another embodiment, the elution rate should be between about 0.01 and 1.0 µ-grams/cm2/day. In a preferred embodiment, the elution rate should be, e.g. about 0.4 µ-grams/cm2/day.
  • In other embodiments, bioactive pharmaceutical agents such as a bronchodilator, an anti-inflammatory agent, or a local anesthetic may be substantially dispersed in a phosphorus-based glass material within a hydrophilic layer. Such bioactive pharmaceutical agents may be delivered to and absorbed by adjacent tissues in substantially the same manner as silver. Regulation and control of dosage, elution rate, and thickness in substantially the same manner as silver may also provide a beneficial pharmacologic or therapeutic action.
  • A hydrophilic coating may be applied to the surface of a medical device by, e.g. dipping, spraying, washing, or painting the hydrophilic coating on the surface. Since the volume of a coating is proportional to the thickness of the coating, however, a hydrophilic surface formed in one of these ways may have only a small volume within which silver is retained. Furthermore, if dipping, spraying, washing, or painting formed the hydrophilic coating, the silver may be present only on the surface of the coating.
  • Since the volume of a coating is necessarily small, the hydrophilic coating may have a limited capacity to hold silver prior to delivery. Furthermore, since the silver may only reside on the surface of the hydrophilic coating, the silver may wash off prematurely, early in the use of the medical device, leaving less silver to prevent future bacteria from becoming sessile and colonizing the surface of the tube.
  • It would be desirable if a hydrophilic layer were extruded or molded along with the medical device, since controlling the thickness of the extrusion or mold could then optimize the volume of the hydrophilic layer.
  • In one embodiment, a medical device may be formed by extruding a wall of hydrophobic material along with one or more layers of an AM material. In another embodiment, a medical device may be formed by molding a wall of hydrophobic material along with one or more layers of an AM material. Standard PVC material may form the wall of the medical device, along with one or more layers of an AM material. The AM layer may be formed on an inner or an outer surface of the medical device wall. The AM layer may be comprised of, e.g. polyurethane, such as a medical grade hydrophilic thermoplastic polyurethane into which has been substantially dispersed a silver bearing phosphorus-based glass material.
  • In one embodiment, the AM layer may be within a range of about 0.002 mm - 2.5 mm in thickness, or about 0.13 mm in thickness. In another embodiment, the AM layer may be within a range of about 0.002 mm - 2.5 mm in thickness. In a third embodiment, the AM layer may be up to about 6.35 mm in thickness. In one embodiment, substantially similar materials may form both the inner and outer surfaces of the tube.
  • In one embodiment, an inner or an outer AM layer may be simultaneously extruded with the medical device wall in a process commonly known as "co-extrusion". In another embodiment, both an inner and an outer AM layer may be extruded simultaneously with the medical device wall in a process sometimes referred to as "tri-extrusion."
  • Applying an AM layer to the surface of a medical device may reduce the incidence of VAR There may also be a production cost savings to be gained by extruding an AM layer on a medical device over a conventional coating process.
  • In one embodiment, an AM layer is also applied to the cuff portion of the medical device. In a preferred embodiment only the outer surface of the cuff will have an AM layer since only the outer surface of the cuff is exposed to the patient. An AM layer may be applied to the outer surface of the cuff portion of the medical device by, e.g. co-extruding the AM layer with the wall of the cuff.
  • The cuff wall may subsequently be expanded to form a thin-walled cuff device. The cuffwall may be expanded by, e.g. a process such as extrusion blow molding. In this process, a core or mandrel of the extruder has apertures to admit a gas such as pressurized air or an inert gas like nitrogen, into the medical device in the neighborhood of the cuff. After a length of medical device, or parison, has been extruded, a mold clamps the medical device around the mandrel. As gas is admitted to the cuff area through the mandrel the cuff expands against the mold. In the alternative, the cuff wall may be expanded in a second discrete expansion process following an extrusion or molding process, such as with a shuttle blowmolding process.
  • In Fig. 2 is shown a medical device 100 according to a first embodiment of the invention. Medical device 100 may be a catheter, a stent, a feeding tube, an intravenous tube, an ET tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic, in various embodiments.
  • Medical device 100 may have a conduit 102 for a fluid and an inflatable cuff 104 disposed at a first end 114 of conduit 102. The fluid may be a gas, an aerosol, a suspension, a vapor, or droplets of liquid dispersed in a gas. A lumen 116 may be disposed alongside conduit 102 to inflate cuff 104. In one embodiment, a wall 112 of conduit 102 is made of a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound.
  • As shown in section 4-4 shown in Fig. 4, a wall 412 of conduit 102 is made of a hydrophobic polymer with an outer layer 406 composed of a hydrophilic polymer and an antimicrobial compound disposed on an outer surface 408 of wall 412. An inner layer 404 composed of a hydrophilic polymer and an antimicrobial compound may further be disposed on an inner surface 410 of wall 412. Outer surface 408 may also be an outer surface of cuff 104.
  • In one embodiment, wall 412 is a hydrophobic compound containing a hydrophilic polymer and an antimicrobial compound. In one embodiment, a hydrophilic polymer and an antimicrobial compound are substantially dispersed, i.e. mixed with a hydrophobic compound forming wall 412 of conduit 102. In another embodiment, hydrophilic polymer and antimicrobial compound are substantially dispersed within cuff 104, with e.g. a hydrophobic compound forming cuff 104.
  • In a second embodiment, a method of making a medical device 100 comprises the actions of providing a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound, combining the hydrophilic polymer and the antimicrobial compound, forming the hydrophobic polymer into a wall 412 of a conduit 102, and substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound as an outer layer 406 on a outer surface 408 of conduit 102.
  • In another embodiment, the method further includes forming the hydrophobic polymer into a cuff 104 on an end of conduit 102, and substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound on a surface of cuff 104.
  • in another embodiment, the method further includes substantially simultaneously extruding the hydrophilic polymer and the antimicrobial compound as an inner layer 404 on an inner surface 410 of conduit 102 while wall 412 and outer layer 406 are being extruded.
  • In one embodiment, a resulting thickness of the hydrophilic polymer and the antimicrobial compound layer 404 is controlled by the extruder. In an alternative embodiment, extruding the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound together forms a wall 412 of conduit 102.
  • In one embodiment, a wall 412 of conduit 102 may be extruded from a hydrophobic compound while an inner layer 404 is extruded in a first predetermined formulation of a hydrophilic polymer and an antimicrobial compound on an inner surface 410 of conduit 102. In another embodiment, a wall 412 of conduit 102 may be extruded from a hydrophobic compound while an outer layer 406 is extruded in a second predetermined formulation of a hydrophilic polymer and an antimicrobial compound on an outer surface 408 of conduit. In an alternative embodiment, an outer layer 406 composed of a hydrophilic polymer and the antimicrobial compound in a second predetermined Formulation may be, e.g. molded on outer surface 408 of conduit 102. In an alternative embodiment, the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be, e.g. compounded together and extruded to form a wall 412 of conduit 102.
  • In one embodiment, the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be, e.g. compounded together and extruded to form a wall 114 of cuff 104. In an alternative embodiment, the hydrophilic polymer and the antimicrobial compound may be, e.g. molded on an outer surface of cuff 104. In an alternative embodiment, the hydrophilic polymer and the antimicrobial compound may be, e.g. extruded on an outer surface of cuff 104. In an alternative embodiment, cuff 104 may be, e.g. formed by extruding the hydrophobic polymer, hydrophilic polymer and antimicrobial compound into a cuff 104, and expanding cuff 104.
  • A system for making a medical device 100 includes means for providing a hydrophobic polymer, means for extruding the hydrophobic polymer to form a wall 412, means for producing an antimicrobial compound comprising a predetermined amount ofphosphorus-based glass having a quantity of silver substantially dispersed therein, means for mixing the antimicrobial compound and a hydrophilic polymer, and means for extruding an outer layer 406 of the hydrophilic polymer having the antimicrobial compound substantially dispersed therein over an outer surface 408 of the wall 412.
  • In one embodiment, conduit 102 is formed by molding the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound in a mold. Either the inner or the outer layers 404, 406, or both, may be molded in a mold with the wall 412. The molding process may be overmolding, insert molding, blow-molding, laminate blow-molding, gas assisted molding, thermoplastic molding, injection molding, or compression molding.
  • A wall 412 may be formed into a tube covered by either an inner or the outer layers 404, 406 and inserted in a mold. The tube maybe be heated in order to promote conformance to the shape of the mold. A fluid such as pressurized air may be pumped into the tube so that the tube is forced or expanded against an inner surface of the mold. A thickness of layers 404 or 406 may be controlled by a clearance between wall 412 and an inner surface of the mold.
  • In one embodiment, a wall 412 and either an inner or outer antimicrobial compound layers 404 and 406 may be forced into a mold cavity to form the medical device. In another embodiment, a wall 412 made of hydrophobic polymer is placed in a mold and the hydrophilic polymer and the antimicrobial compound layers 404 and 406 are molded around it.
  • In Fig. 3 is shown an extruder 300 for use with an embodiment of the invention. Fig. 3 may include a main extruder 302 to extrude hydrophobic polymer for the wall 412, a satellite extruder 304 for the AM material, and a satellite extruder 306 for a radio-opaque material. Satellite extruder 304 may feed matching gear pumps 308 to split the AM material into separate layers, one of which may be an inner layer 404 and the other an outer layer 406. A head 310 collects the material streams from the individual satellite extruders, combines them with the flow of material for wall 412 and extrudes them into a medical device 100.
  • While the invention has been described in detail above, the invention is not intended to be limited to the specific embodiments as described. It is evident that those skilled in the art may now make numerous uses and modifications of and departures from the specific embodiments described herein without departing from the claimed subject-matter.

Claims (19)

  1. A medical device comprising:
    a conduit (102) for a fluid;
    said conduit (102) comprising a wall (112) having an outer surface (408), said wall (112) comprising a hydrophobic polymer; and
    an outer layer (406) disposed on said outer surface (408), said outer layer (406) comprising a first quantity of a hydrophilic polymer having an antimicrobial compound substantially dispersed therein;
    characterized in that said antimicrobial compound comprises a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein; and
    said wall (112) and said outer layer (406) are formed by extrusion or molding.
  2. The medical device according to claim 1, wherein said molding is overmolding, insert molding, blow-molding, laminate blow-molding, injection molding, or compression molding.
  3. The medical device according to claim 1 or 2, wherein said metal is copper, gold, powdered silver, substantially elemental silver, silver ions, silver oxide, or any combination thereof.
  4. The medical device according to claim 1, 2 or 3, wherein said wall (112) further comprises an inner surface (410);
    an inner layer (404) disposed on said inner surface (410), said inner layer (404) comprising a second quantity of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein; and
    wherein said inner layer (404) is formed by extrusion.
  5. The medical device according to claim 4, wherein a thickness of said inner layer (404) is within a range of about 0.002 mm - 2.5 mm.
  6. The medical device according to any of the preceding claims, wherein a thickness of said outer layer (406) is within a range of about 0.002 mm - 2.5 mm.
  7. The medical device according to any of the preceding claims, wherein a third quantity of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein is substantially dispersed within said wall (112).
  8. The medical device according to any of the preceding claims, comprising further a cuff (104) having a cuff outer surface disposed around said medical device, a cuff outer layer disposed on said cuff outer surface, said cuff outer layer comprising a fourth quantity of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein; and
    wherein said cuff outer layer is formed by extrusion.
  9. The medical device according to any of the preceding claims, wherein said hydrophilic polymer comprises polyurethane or medical grade hydrophilic thermoplastic polyurethane.
  10. The medical device according to any of the preceding claims, wherein said metal is releasable from said antimicrobial compound.
  11. The medical device according to claim 10, wherein said metal is released at an elution rate of up to about 0.01 µ-grams/cm2/day, at an elution rate of between about 0.01 and about 1.0 µ-grams/cm2/day, or at an elution rate of about 0.4 µ-grams/cm2/day.
  12. The medical device according to any of the preceding claims, wherein said predetermined amount of phosphorus-based glass comprises about 0.1 - 50 % of a weight of said antimicrobial compound.
  13. The medical device according to any of the preceding claims, wherein said hydrophobic polymer comprises PVC, PE, PU, PDMS, polyester, silicone, or rubber.
  14. The medical device according to any of the preceding claims, wherein said medical device comprises an endotracheal tube.
  15. The medical device according to any of the preceding claims, wherein said medical device is a catheter, a stent, a feeding tube, a breathing circuit, an intravenous tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic.
  16. The medical device according to any of the preceding claims, wherein said antimicrobial compound comprises further an agent in form of an indicator of a carbon dioxide concentration, a bronchodilator, an anti-inflammatory agent, or a local anesthetic.
  17. A method of making the medical device of any one of the preceding claims, comprising the steps of:
    providing the hydrophobic polymer;
    extruding said hydrophobic polymer to form the wall (112) of the conduit (102);
    producing the antimicrobial compound comprising a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal substantially dispersed therein;
    mixing said antimicrobial compound and a hydrophilic polymer; and
    extruding a layer (406) of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein over an outer surface (408) of said wall (112).
  18. The method of making the medical device according to claim 17, further comprising the step of extruding a layer (404) of said hydrophilic polymer having said antimicrobial compound substantially dispersed therein over an inner surface (410) of said wall (112).
  19. The method of making the medical device according to claim 17 or 18, further comprising the step of forming a cuff (104) on an end of said conduit.
EP04760444A 2003-04-29 2004-04-29 Medical device with antimicrobial layer Expired - Lifetime EP1617890B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/425,030 US20040220534A1 (en) 2003-04-29 2003-04-29 Medical device with antimicrobial layer
PCT/US2004/013196 WO2004096330A2 (en) 2003-04-29 2004-04-29 Medical device with antimicrobial layer

Publications (2)

Publication Number Publication Date
EP1617890A2 EP1617890A2 (en) 2006-01-25
EP1617890B1 true EP1617890B1 (en) 2010-06-30

Family

ID=33309638

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04760444A Expired - Lifetime EP1617890B1 (en) 2003-04-29 2004-04-29 Medical device with antimicrobial layer

Country Status (8)

Country Link
US (4) US20040220534A1 (en)
EP (1) EP1617890B1 (en)
JP (1) JP2006525089A (en)
AT (1) ATE472343T1 (en)
AU (1) AU2004234001B2 (en)
CA (1) CA2523857A1 (en)
DE (1) DE602004027899D1 (en)
WO (1) WO2004096330A2 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626830A1 (en) * 1998-02-24 1999-08-26 Boston Scientific Limited High flow rate dialysis catheters and related methods
US20050191355A1 (en) * 1999-05-27 2005-09-01 Foss Manufacturing Co., Inc. Anti-microbial and antifungal fluid conduits and methods of manufacture thereof
US20090165784A1 (en) * 2007-12-28 2009-07-02 Tyco Healthcare Group Lp Lubricious intubation device
US20040220534A1 (en) * 2003-04-29 2004-11-04 Martens Paul W. Medical device with antimicrobial layer
US20040254545A1 (en) * 2003-06-16 2004-12-16 Rider Dean Loller Method and apparatus for extending feeding tube longevity
DE102004025671A1 (en) * 2004-05-26 2005-12-22 Map Medizin-Technologie Gmbh Arrangement for administering a respirable gas, in particular CPAP device arrangement
ZA200700374B (en) * 2004-06-18 2008-08-27 Boc Group Inc Antimicrobial lining for gas cylinders and coupling components
US9457163B2 (en) 2004-09-03 2016-10-04 Virginia Commonwealth University Prevention of ventilator associated pneumonia (VAP)
WO2006029070A2 (en) * 2004-09-03 2006-03-16 Virginia Commonwealth University Prevention of ventilator associated pneumonia (vap)
WO2006089961A1 (en) * 2005-02-28 2006-08-31 Tracoe Medical Gmbh Inhaled air supplying device
US20070135751A1 (en) * 2005-12-09 2007-06-14 Dicarlo Paul D Medical devices
US11229746B2 (en) 2006-06-22 2022-01-25 Excelsior Medical Corporation Antiseptic cap
US8434487B2 (en) * 2006-06-22 2013-05-07 Covidien Lp Endotracheal cuff and technique for using the same
US8196584B2 (en) * 2006-06-22 2012-06-12 Nellcor Puritan Bennett Llc Endotracheal cuff and technique for using the same
US20080236593A1 (en) * 2006-06-22 2008-10-02 Nellcor Puritan Bennett Llc Endotracheal cuff and technique for using the same
US20080051759A1 (en) * 2006-08-24 2008-02-28 Boston Scientific Scimed, Inc. Polycarbonate polyurethane venous access devices
US8561614B2 (en) * 2006-09-28 2013-10-22 Covidien Lp Multi-layer cuffs for medical devices
US20080078406A1 (en) * 2006-09-29 2008-04-03 Jessica Clayton Endotracheal tube and technique for using the same
US10188826B2 (en) * 2006-09-29 2019-01-29 Covidien Lp Catheters including antimicrobial sleeve and methods of making catheters
PL1935355T3 (en) * 2006-12-11 2016-03-31 Nutricia Nv Tube for enteral nutrition
US20090014009A1 (en) * 2007-07-13 2009-01-15 Kimberly-Clark Worldwide, Inc. Toroidal endotracheal cuffs for ventilator associated pneumonia reduction
US8607795B2 (en) 2007-09-20 2013-12-17 Kimberly-Clark Worldwide, Inc. Balloon cuff tracheostomy tube
US8313687B2 (en) 2007-09-20 2012-11-20 Kimberly-Clark Worldwide, Inc. Method of making an improved balloon cuff tracheostomy tube
WO2009049266A2 (en) 2007-10-12 2009-04-16 Conmed Corporation Apparatus and methods for the measurement of cardiac output
WO2009052506A1 (en) * 2007-10-19 2009-04-23 Navilyst Medical, Inc. Recirculation minimizing catheter
US8186351B2 (en) 2007-12-31 2012-05-29 Nellcor Puritan Bennett Llc Reactive medical devices
US9078992B2 (en) 2008-10-27 2015-07-14 Pursuit Vascular, Inc. Medical device for applying antimicrobial to proximal end of catheter
US20100256546A1 (en) * 2009-04-03 2010-10-07 Davis Scott A Polycarbonate Polyurethane Venous Access Devices Having Enhanced Strength
US8590534B2 (en) 2009-06-22 2013-11-26 Covidien Lp Cuff for use with medical tubing and method and apparatus for making the same
US8821455B2 (en) * 2009-07-09 2014-09-02 Becton, Dickinson And Company Antimicrobial coating for dermally invasive devices
US8715705B2 (en) * 2009-07-29 2014-05-06 Covidien Lp Multilayer medical devices having an encapsulated edge and methods thereof
US8328760B2 (en) * 2010-01-11 2012-12-11 Angiodynamics, Inc. Occlusion resistant catheter
ES2584323T3 (en) 2010-01-28 2016-09-27 Art Healthcare Ltd. Reflux detection and / or blocking device
WO2011116303A1 (en) 2010-03-19 2011-09-22 Micropen Technologies Corporation Thermocouple device
JP5970448B2 (en) * 2010-03-22 2016-08-17 アート ヘルスケア リミテッド Endotracheal tube having one or more blocking elements, blocking elements, and methods of using blocking elements
WO2011117853A1 (en) * 2010-03-22 2011-09-29 Art Healthcare Ltd. Naso/orogastric tube having one or more backflow blocking elements, backflow blocking elements, and a method of using backflow blocking elements
US9878143B2 (en) * 2010-09-30 2018-01-30 Covidien Lp Antimicrobial luer adapter
US9050435B2 (en) 2011-03-22 2015-06-09 Angiodynamics, Inc. High flow catheters
US9999746B2 (en) 2011-03-22 2018-06-19 Angiodynamics, Inc. High flow catheters
US10166381B2 (en) 2011-05-23 2019-01-01 Excelsior Medical Corporation Antiseptic cap
WO2013009998A2 (en) 2011-07-12 2013-01-17 Pursuit Vascular, Inc. Device for delivery of antimicrobial agent into trans-dermal catheter
US9242058B2 (en) 2011-07-29 2016-01-26 Covidien Lp Tracheal tube positioning devices and methods
CN103877624B (en) 2012-12-21 2016-05-25 上海微创医疗器械(集团)有限公司 A kind of degradable polyester support and preparation method thereof
EP3137122B1 (en) 2014-05-02 2019-09-04 Excelsior Medical Corporation Strip package for antiseptic cap
GB201416891D0 (en) * 2014-09-25 2014-11-12 Smiths Medical Int Ltd Tracheal Tubes And Seals
US20160101253A1 (en) * 2014-10-08 2016-04-14 Husam Ibrahim ALAHMADI Protective endotracheal tube
CA2980020C (en) 2015-03-30 2023-08-01 Giridhar Thiagarajan Application of antimicrobial agents to medical devices
US20180104157A1 (en) * 2015-04-17 2018-04-19 Evolve Biosystems, Inc. Delivering non-pathogenic, intestinally beneficial bacteria to a patient having a feeding tube
JP6822978B2 (en) 2015-05-08 2021-01-27 アイシーユー・メディカル・インコーポレーテッド Medical connector configured to accept the emitter of a therapeutic agent
US10064273B2 (en) 2015-10-20 2018-08-28 MR Label Company Antimicrobial copper sheet overlays and related methods for making and using
KR101753299B1 (en) * 2016-01-26 2017-07-03 연세대학교 산학협력단 Endotracheal tube and Endotracheal tube assembly
CN107929902A (en) * 2016-03-21 2018-04-20 周中南 Trachea cannula tube core and preparation method thereof
LT3484535T (en) 2016-07-14 2022-02-10 Hollister Incorporated Hygienic medical devices having hydrophilic coating and methods of forming the same
CA3040277A1 (en) 2016-10-14 2018-04-19 Icu Medical, Inc. Sanitizing caps for medical connectors
WO2018204206A2 (en) 2017-05-01 2018-11-08 Icu Medical, Inc. Medical fluid connectors and methods for providing additives in medical fluid lines
CN107899089B (en) * 2018-01-22 2021-03-26 上海士宇生物技术有限公司 T-shaped trachea cannula containing mitomycin and having scar preventing function and preparation method thereof
CN215915829U (en) 2018-07-02 2022-03-01 C·R·巴德股份有限公司 Antimicrobial catheter assembly
US11524098B2 (en) * 2018-09-14 2022-12-13 Avent, Inc. Systems and methods for biofilm inoculation
US11534595B2 (en) 2018-11-07 2022-12-27 Icu Medical, Inc. Device for delivering an antimicrobial composition into an infusion device
US11517732B2 (en) 2018-11-07 2022-12-06 Icu Medical, Inc. Syringe with antimicrobial properties
US11400195B2 (en) 2018-11-07 2022-08-02 Icu Medical, Inc. Peritoneal dialysis transfer set with antimicrobial properties
US11541220B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Needleless connector with antimicrobial properties
US11541221B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Tubing set with antimicrobial properties
AU2019384564B2 (en) 2018-11-21 2023-11-23 Icu Medical, Inc. Antimicrobial device comprising a cap with ring and insert
JP2020092911A (en) * 2018-12-13 2020-06-18 大塚テクノ株式会社 Urethral catheter
USD930831S1 (en) 2020-03-05 2021-09-14 Jim Benton Microbial barrier tubing clamp
CA3204371A1 (en) 2020-12-07 2022-06-16 Icu Medical, Inc. Peritoneal dialysis caps, systems and methods

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US691104A (en) * 1901-03-14 1902-01-14 Thomas E Woodley Machine for finishing heels and bottoms.
US909002A (en) * 1908-06-03 1909-01-05 Napoleon Lambert Respirator.
US1796124A (en) * 1927-11-30 1931-03-10 Bristol Company Temperature controller
US3173418A (en) * 1961-01-10 1965-03-16 Ostap E Baran Double-wall endotracheal cuff
FR1453843A (en) * 1965-03-18 1966-07-22 Pechiney Saint Gobain New compounds with parasiticidal action
FR1472949A (en) * 1965-06-29 1967-03-17 Pechiney Saint Gobain New parasiticidal ketoacetylenic products
FR2048177A5 (en) * 1969-06-03 1971-03-19 Pechiney Saint Gobain
US3734100A (en) * 1973-05-07 1973-05-22 Medical Products Corp Catheter tubes
US4343788A (en) * 1979-06-29 1982-08-10 The Procter & Gamble Company Antimicrobial polymer compositions
US4328056A (en) * 1980-07-09 1982-05-04 Sherwood Medical Industries Inc. Method of making a cuffed tube
US4379863A (en) * 1981-01-13 1983-04-12 C. R. Bard, Inc. Copolymer composition and delivery system for providing a protective barrier film for the skin
US4539234A (en) * 1981-05-27 1985-09-03 Unitika Ltd. Urethral catheter capable of preventing urinary tract infection and process for producing the same
US4515593A (en) * 1981-12-31 1985-05-07 C. R. Bard, Inc. Medical tubing having exterior hydrophilic coating for microbiocide absorption therein and method for using same
US4417892A (en) * 1981-12-31 1983-11-29 C. R. Bard, Inc. Urine drainage bag outlet tube and method for eliminating or reducing migration of bacteria
SE430695B (en) * 1982-04-22 1983-12-05 Astra Meditec Ab PROCEDURE FOR THE PREPARATION OF A HYDROPHILIC COATING AND ACCORDING TO THE PROCEDURE OF MEDICAL ARTICLES
US4603152A (en) * 1982-11-05 1986-07-29 Baxter Travenol Laboratories, Inc. Antimicrobial compositions
JPS59133235A (en) * 1983-01-21 1984-07-31 Kanebo Ltd Zeolite particle-containing polymer and its production
US4512765A (en) * 1983-06-09 1985-04-23 Rudolph Muto Selective tracheal bronchial catheter
US4686124A (en) * 1983-12-12 1987-08-11 Sumitomo Bakelite Company Ltd. Thermoplastic resin-silicone rubber composite shaped article
US4563485A (en) * 1984-04-30 1986-01-07 The Trustees Of Columbia University In The City Of New York Injection-resistant materials and method of making same through use of nalidixic acid derivatives
US4581028A (en) * 1984-04-30 1986-04-08 The Trustees Of Columbia University In The City Of New York Infection-resistant materials and method of making same through use of sulfonamides
US4584192A (en) * 1984-06-04 1986-04-22 Minnesota Mining & Manufacturing Company Film-forming composition containing an antimicrobial agent and methods of use
US4723950A (en) * 1984-12-12 1988-02-09 C. R. Bard, Inc. Urine drainage bag outlet with barrier against microbial infection
US4642267A (en) * 1985-05-06 1987-02-10 Hydromer, Inc. Hydrophilic polymer blend
SE8504501D0 (en) * 1985-09-30 1985-09-30 Astra Meditec Ab METHOD OF FORMING AN IMPROVED HYDROPHILIC COATING ON A POLYMER SURFACE
US4917686A (en) * 1985-12-16 1990-04-17 Colorado Biomedical, Inc. Antimicrobial device and method
GB8616294D0 (en) * 1986-07-03 1986-08-13 Johnson Matthey Plc Antimicrobial compositions
US4728323A (en) * 1986-07-24 1988-03-01 Minnesota Mining And Manufacturing Company Antimicrobial wound dressings
US4895566A (en) * 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
US5290548A (en) * 1987-04-10 1994-03-01 University Of Florida Surface modified ocular implants, surgical instruments, devices, prostheses, contact lenses and the like
US4806382A (en) * 1987-04-10 1989-02-21 University Of Florida Ocular implants and methods for their manufacture
US5100689A (en) * 1987-04-10 1992-03-31 University Of Florida Surface modified surgical instruments, devices, implants, contact lenses and the like
US5108776A (en) * 1987-04-10 1992-04-28 University Of Florida Ocular implants and methods for their manufacture
US5080893A (en) * 1988-05-31 1992-01-14 University Of Florida Method for preventing surgical adhesions using a dilute solution of polymer
US5306289A (en) * 1987-08-26 1994-04-26 United States Surgical Corporation Braided suture of improved characteristics
GB8720502D0 (en) * 1987-08-29 1987-10-07 Giltech Ltd Antimicrobial composition
US5201724A (en) * 1987-12-23 1993-04-13 The Victoria University Of Manchester Catheter
US5019096A (en) * 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US4994047A (en) * 1988-05-06 1991-02-19 Menlo Care, Inc. Multi-layer cannula structure
US5124129A (en) * 1988-07-29 1992-06-23 Mallinckrodt Medical, Inc. Carbon dioxide indicator
GB8820945D0 (en) * 1988-09-07 1988-10-05 Smith & Nephew Medical articles
US5888441A (en) * 1988-08-24 1999-03-30 Ansell Healthcare Products Inc. Preparation of antimicrobial articles
US5091205A (en) * 1989-01-17 1992-02-25 Union Carbide Chemicals & Plastics Technology Corporation Hydrophilic lubricious coatings
US4999210A (en) * 1989-01-18 1991-03-12 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US6261271B1 (en) * 1989-01-18 2001-07-17 Becton Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
IE64997B1 (en) * 1989-01-18 1995-10-04 Becton Dickinson Co Anti-infection and antithrombogenic medical articles and method for their preparation
US5165952A (en) * 1989-01-18 1992-11-24 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US4925668A (en) * 1989-01-18 1990-05-15 Becton, Dickinson And Company Anti-infective and lubricious medical articles and method for their preparation
US5013306A (en) * 1989-01-18 1991-05-07 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5181505A (en) * 1989-03-08 1993-01-26 Lew Chel W Method and apparatus for delivery of a medicament in the oral cavity
US4990357A (en) * 1989-05-04 1991-02-05 Becton, Dickinson And Company Elastomeric segmented hydrophilic polyetherurethane based lubricious coatings
US4990158A (en) * 1989-05-10 1991-02-05 United States Surgical Corporation Synthetic semiabsorbable tubular prosthesis
US5061254A (en) * 1989-06-21 1991-10-29 Becton, Dickinson And Company Thermoplastic elastomeric hydrophilic polyetherurethane expandable catheter
JP2752465B2 (en) * 1989-10-20 1998-05-18 三菱化学株式会社 Manufacturing method of antibacterial polyolefin resin molded product
US5089205A (en) * 1989-09-25 1992-02-18 Becton, Dickinson And Company Process for producing medical devices having antimicrobial properties
US5049132A (en) * 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US5181923A (en) * 1990-03-26 1993-01-26 United States Surgical Corporation Spiroid braided suture
US5102983A (en) * 1990-04-02 1992-04-07 United States Surgical Corporation Process for preparing foamed, bioabsorbable polymer particles
US5179174A (en) * 1990-04-23 1993-01-12 C. R. Bard, Inc. Flexible lubricious organic coatings
WO1991017724A1 (en) * 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
US5279594A (en) * 1990-05-23 1994-01-18 Jackson Richard R Intubation devices with local anesthetic effect for medical use
US5328698A (en) * 1990-08-06 1994-07-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic and/or anti-infective
US5302392A (en) * 1990-08-20 1994-04-12 Becton, Dickinson And Company Polyurethane sponge having rapid iodine release
US5302385A (en) * 1990-08-20 1994-04-12 Becton, Dickinson And Company Polyurethane-polyvinylpyrrolidone block copolymer and iodine carrier therefrom
US5102401A (en) * 1990-08-22 1992-04-07 Becton, Dickinson And Company Expandable catheter having hydrophobic surface
US5160790A (en) * 1990-11-01 1992-11-03 C. R. Bard, Inc. Lubricious hydrogel coatings
DE4105235A1 (en) * 1991-02-20 1992-08-27 Merck Patent Gmbh COATED SYSTEM
US5296238A (en) * 1991-02-26 1994-03-22 Toagosei Chemical Industry Co., Inc. Microbicides
AU1579092A (en) * 1991-02-27 1992-10-06 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
US5038777A (en) * 1991-03-14 1991-08-13 Dunn Margarette T Endotracheal device
US5443907A (en) * 1991-06-18 1995-08-22 Scimed Life Systems, Inc. Coating for medical insertion guides
FR2679142B1 (en) * 1991-07-18 1995-06-09 Nice Sophia Antipolis Universi PROCESS FOR THE PROTECTION OF PROSTHESES, IMPLANTABLE PROVISIONAL OR DEFINITIVE MATERIALS AGAINST COLONIZATION AND BACTERIAL INFECTION.
US5282829A (en) * 1991-08-15 1994-02-01 United States Surgical Corporation Hollow body implants
US5275618A (en) * 1991-11-13 1994-01-04 United States Surgical Corporation Jet entangled suture yarn and method for making same
US5250620A (en) * 1991-11-21 1993-10-05 Miles Inc. Hydrophilic polyvinylpyrrolidone compositions having a low coefficient of friction
JPH05220216A (en) * 1992-02-15 1993-08-31 Kawasumi Lab Inc In vivo insertion tube
US5225485A (en) * 1992-03-03 1993-07-06 United States Surgical Corporation Polyetherimide ester suture and its method of manufacture and method of use
US5569184A (en) * 1992-04-29 1996-10-29 Cardiovascular Dynamics, Inc. Delivery and balloon dilatation catheter and method of using
US5492763A (en) * 1992-06-08 1996-02-20 Spire Corporation Infection resistant medical devices and process
DE4226810C1 (en) * 1992-08-13 1994-01-27 Theodor Dipl Ing Krall Hoses and other objects made of plastic for medical use, which are not colonized by germs and processes for their manufacture
US5284489A (en) * 1992-08-19 1994-02-08 United States Surgical Corporation Filament fabricated from a blend of ionomer resin and nonionic thermoplastic resin
PT590348E (en) * 1992-09-26 2002-07-31 Aventis Bulk S P A CATHETERS OF CENTRAL VEINS CHARGED WITH LIPODALBA-HEPTIDEO ANTIBIOTICS TO PREVENT THE DEVELOPMENT OF CATHETER RELATED INFECTIONS
US5599291A (en) * 1993-01-04 1997-02-04 Menlo Care, Inc. Softening expanding ureteral stent
US5349045A (en) * 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
US5848995A (en) * 1993-04-09 1998-12-15 Walder; Anthony J. Anti-infective medical article and method for its preparation
DE4316920A1 (en) * 1993-05-20 1994-11-24 Michael Dr Med Hartmann Endotracheal tube
US5403347A (en) * 1993-05-27 1995-04-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
NZ533467A (en) * 1993-07-19 2006-02-24 Angiotech Pharm Inc Anti-angiogenic compositions and methods of use
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5395398A (en) * 1993-07-28 1995-03-07 C. R. Bard, Inc. Microelectric apparatus for the antisepsis, promulgation of healing and analgesia of wound and chronic skin ulcers
US6361526B1 (en) * 1993-11-01 2002-03-26 Medtronic Xomed, Inc. Antimicrobial tympanostomy tube
EP0735852B1 (en) * 1993-12-20 1999-09-22 Biopolymerix, Inc. Liquid dispenser for sterile solutions
US5554147A (en) * 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5976562A (en) * 1994-02-01 1999-11-02 Krall; Theodor Process for producing bactericidal/fungicidal plastic bodies
US5505952A (en) * 1994-04-19 1996-04-09 United States Surgical Corporation Modified synthetic cross-linked amino acid polymers and medical devices formed therefrom
US5502042A (en) * 1994-07-22 1996-03-26 United States Surgical Corporation Methods and compositions for treating wounds
US6339130B1 (en) * 1994-07-22 2002-01-15 United States Surgical Corporation Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US5480963A (en) * 1994-07-22 1996-01-02 United States Surgical Corporation Absorbable copolymers derived from tricarboxylic acids and surgical articles made therefrom
US6046143A (en) * 1994-08-22 2000-04-04 Becton Dickinson And Company Water soluble lubricant for medical devices
US5507777A (en) * 1994-10-07 1996-04-16 United States Surgical Corporation Method and apparatus for treating a portion of a suture and forming a suture tip for attachment to a needle
US5618313A (en) * 1994-10-11 1997-04-08 United States Surgical Corporation Absorbable polymer and surgical articles fabricated therefrom
JPH08117327A (en) * 1994-10-20 1996-05-14 Nippon Zeon Co Ltd Medical instrument to be retained intravescularly
US5480961A (en) * 1994-11-03 1996-01-02 United States Surgical Corporation Bioabsorbable polymers derived from cyclic ether esters and surgical articles made therefrom
US5614310A (en) * 1994-11-04 1997-03-25 Minnesota Mining And Manufacturing Company Low trauma wound dressing with improved moisture vapor permeability
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US6169138B1 (en) * 1994-12-15 2001-01-02 Saint-Gobain Performance Plastics Corporation Foamed pressure sensitive tapes
US6017577A (en) * 1995-02-01 2000-01-25 Schneider (Usa) Inc. Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices
GB9502253D0 (en) * 1995-02-06 1995-03-29 Giltech Ltd The effects of antibacterial agents on the behaviour of mouse fibroblasts in vitro
GB9511233D0 (en) * 1995-06-03 1995-07-26 Watson Jermey Lubricious coatings
US5643628A (en) * 1995-06-05 1997-07-01 United States Surgical Corporation Suture tipping apparatus and method
AU6251196A (en) * 1995-06-07 1996-12-30 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical dev ice and method for loading and reloading the device therein
US5731087A (en) * 1995-06-07 1998-03-24 Union Carbide Chemicals & Plastics Technology Corporation Lubricious coatings containing polymers with vinyl and carboxylic acid moieties
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5620738A (en) * 1995-06-07 1997-04-15 Union Carbide Chemicals & Plastics Technology Corporation Non-reactive lubicious coating process
US5744151A (en) * 1995-06-30 1998-04-28 Capelli; Christopher C. Silver-based pharmaceutical compositions
FR2738813B1 (en) * 1995-09-15 1997-10-17 Saint Gobain Vitrage SUBSTRATE WITH PHOTO-CATALYTIC COATING
CZ297518B6 (en) * 1995-09-15 2007-01-03 Rhodia Chimie Substrate provided with coating exhibiting photocatalytic properties, glazing material containing such substrate, use of said substrate, process for producing thereof, dispersion for the production process as well as use of such dispersion in the pro
US5894042A (en) * 1996-02-26 1999-04-13 Technology Licensing Company Bacteriostatic coating of polymeric conduit
US5709691A (en) * 1996-03-11 1998-01-20 Morejon; Orlando Endotracheal tube cleaning device
US6494208B1 (en) * 1996-03-11 2002-12-17 Orlando Morejon Endotracheal tube cleaning apparatus
US20040081706A1 (en) * 1996-03-13 2004-04-29 Eilidh Trainer Alginate containing antimicrobial composition
US5727553A (en) * 1996-03-25 1998-03-17 Saad; Saad A. Catheter with integral electromagnetic location identification device
US6461644B1 (en) * 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
GB9607201D0 (en) * 1996-04-04 1996-06-12 Boc Group Plc Medical article
US6033719A (en) * 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
US5891506A (en) * 1996-08-09 1999-04-06 Medtronic, Inc. Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices
US5728420A (en) * 1996-08-09 1998-03-17 Medtronic, Inc. Oxidative method for attachment of glycoproteins to surfaces of medical devices
US5945319A (en) * 1996-04-25 1999-08-31 Medtronic, Inc. Periodate oxidative method for attachment of biomolecules to medical device surfaces
US5925552A (en) * 1996-04-25 1999-07-20 Medtronic, Inc. Method for attachment of biomolecules to medical devices surfaces
US6628987B1 (en) * 2000-09-26 2003-09-30 Medtronic, Inc. Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia
CA2206674A1 (en) * 1996-05-30 1997-11-30 Gregor Reid Lactobacillus therapies
US5811151A (en) * 1996-05-31 1998-09-22 Medtronic, Inc. Method of modifying the surface of a medical device
US5891167A (en) * 1996-06-19 1999-04-06 United States Surgical Corporation Collagen coated gut suture
JP3541627B2 (en) * 1996-07-16 2004-07-14 東レ株式会社 Graft polymer and molded article for medical use using the same
US5993972A (en) * 1996-08-26 1999-11-30 Tyndale Plains-Hunter, Ltd. Hydrophilic and hydrophobic polyether polyurethanes and uses therefor
US6017334A (en) * 1996-10-03 2000-01-25 Board Of Regents, The University Of Texas System Modified surfaces resistant to bacterial colonization
US6191236B1 (en) * 1996-10-11 2001-02-20 United States Surgical Corporation Bioabsorbable suture and method of its manufacture
US6530951B1 (en) * 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6685943B1 (en) * 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
JPH10323386A (en) * 1997-03-21 1998-12-08 Nippon Sherwood Medical Ind Ltd Antibacterial catheter against blood coagulation
KR100246927B1 (en) * 1997-06-10 2000-03-15 손욱 Composition of single-layer typed light conductive layer using charge transfering adhesive body system and manufacturing method thereof
US5928174A (en) * 1997-11-14 1999-07-27 Acrymed Wound dressing device
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6526977B1 (en) * 1998-03-09 2003-03-04 Goebel Fred G. Tracheal breathing apparatus
US6176894B1 (en) * 1998-06-17 2001-01-23 Praxair Technology, Inc. Supersonic coherent gas jet for providing gas into a liquid
AU5153399A (en) * 1998-08-14 2000-03-06 Coloplast A/S Stabilised compositions having antibacterial activity
US6273875B1 (en) * 1998-08-17 2001-08-14 Edwards Lifesciences Corporation Medical devices having improved antimicrobial/antithrombogenic properties
US6436422B1 (en) * 1998-11-23 2002-08-20 Agion Technologies L.L.C. Antibiotic hydrophilic polymer coating
WO2000051566A1 (en) * 1999-03-04 2000-09-08 United States Surgical Corporation Scar reduction
US20010041870A1 (en) * 1999-03-09 2001-11-15 Edward M. Gillis Implantable device for access to a treatment site
AU3771000A (en) * 1999-03-25 2000-10-09 United States Surgical Corporation Method of promoting angiogenesis
US6168580B1 (en) * 1999-03-26 2001-01-02 Iontophoretics Corporation Antimicrobial device and methods for long-term catheters
JP4014334B2 (en) * 1999-04-23 2007-11-28 株式会社Adeka Antibacterial deodorant cosmetic
PT1196150E (en) * 1999-06-14 2005-11-30 Imp College Innovations Ltd BIOACTIVE GLASS COMPOSITIONS DERIVED FROM SOL-GEL CONTAINING SILVER
JP3971059B2 (en) * 1999-07-15 2007-09-05 東亞合成株式会社 Glass antibacterial agent
US6475631B1 (en) * 1999-07-15 2002-11-05 Toagosei Co., Ltd. Antimicrobial agent, antimicrobial resin composition and antimicrobial artificial marble
WO2001006973A1 (en) * 1999-07-28 2001-02-01 United States Surgical Corporation Hyaluronic acid anti-adhesion barrier
US20040038327A1 (en) * 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
GB9924694D0 (en) * 1999-10-20 1999-12-22 Giltech Ltd Anti-microbial device
US6471672B1 (en) * 1999-11-10 2002-10-29 Scimed Life Systems Selective high pressure dilation balloon
US20060013850A1 (en) * 1999-12-03 2006-01-19 Domb Abraham J Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom
US6677431B2 (en) * 1999-12-10 2004-01-13 The Trustees Of The University Of Pennsylvania Design, preparation, and properties of antibacterial β-peptides
US6716895B1 (en) * 1999-12-15 2004-04-06 C.R. Bard, Inc. Polymer compositions containing colloids of silver salts
US6517838B1 (en) * 2000-06-16 2003-02-11 The Texas A&M University System Decorin binding protein essential peptides and methods of use
US6989189B2 (en) * 2000-06-30 2006-01-24 Mondi Inncoat Gmbh Separable layer of bonding material, laminate and method for making same
US6443156B1 (en) * 2000-08-02 2002-09-03 Laura E. Niklason Separable double lumen endotracheal tube
US6450164B1 (en) * 2000-08-17 2002-09-17 Michael J. Banner Endotracheal tube pressure monitoring system and method of controlling same
GB0023131D0 (en) * 2000-09-21 2000-11-01 Hunter Gary F Catheters
US6855422B2 (en) * 2000-09-21 2005-02-15 Monte C. Magill Multi-component fibers having enhanced reversible thermal properties and methods of manufacturing thereof
US6487446B1 (en) * 2000-09-26 2002-11-26 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US6797743B2 (en) * 2000-09-27 2004-09-28 Michigan Biotechnology Institute Antimicrobial polymer
NZ526821A (en) * 2001-01-18 2005-02-25 Genzyme Corp Ionene polymers and their use as antimicrobial agents
FR2821140B1 (en) * 2001-02-16 2003-05-23 Syegon PILOTED PNEUMATIC VALVE
US7393547B2 (en) * 2001-04-11 2008-07-01 Helix Medical, Llc Antimicrobial elastomer composition and method for making
EP1443957A4 (en) * 2001-05-08 2005-10-12 Texas A & M Univ Sys Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them
US6716207B2 (en) * 2001-05-22 2004-04-06 Scimed Life Systems, Inc. Torqueable and deflectable medical device shaft
US6576329B2 (en) * 2001-06-12 2003-06-10 Exxonmobil Oil Corporation Multilayer thermoplastic film
US6787179B2 (en) * 2001-06-29 2004-09-07 Ethicon, Inc. Sterilization of bioactive coatings
JP5041636B2 (en) * 2001-07-12 2012-10-03 株式会社Adeka Antimicrobial composition for medical devices
US6629969B2 (en) * 2001-07-26 2003-10-07 Durect Corporation Catheter for modification of agent formulation
AU2002367825A1 (en) * 2001-07-30 2003-10-13 Sts Biopolymers, Inc. Graft polymer matrices
US20030100829A1 (en) * 2001-11-27 2003-05-29 Sheng-Ping Zhong Medical devices with magnetic resonance visibility enhancing material
JP2005536185A (en) * 2002-03-05 2005-12-02 インヒビテックス インコーポレーテッド Monoclonal and polyclonal antibodies that recognize coagulase-negative staphylococcal proteins
US20040022775A1 (en) * 2002-04-15 2004-02-05 Gregor Reid Methods of treating viral infections in mammals
FR2838734B1 (en) * 2002-04-17 2005-04-15 Saint Gobain SELF-CLEANING COATING SUBSTRATE
US7393501B2 (en) * 2002-05-29 2008-07-01 Nano Vibronix Inc Method, apparatus and system for treating biofilms associated with catheters
WO2004013167A2 (en) * 2002-08-01 2004-02-12 Affinium Pharmaceuticals, Inc. Purified polypeptides from enterococcus faecalis
US7238669B2 (en) * 2002-09-11 2007-07-03 The Curators Of The University Of Missouri Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae
US6770729B2 (en) * 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
AU2003291087A1 (en) * 2002-11-19 2004-06-15 Genzyme Corporation Ionene oligomers and polymers
AU2003295636A1 (en) * 2002-11-19 2004-06-15 Genzyme Corporation Polyionene polymers with hydrolyzable linkages
BRPI0407142A (en) * 2003-02-14 2006-01-10 Depuy Spine Inc In situ intervertebral fusion device
JP4293806B2 (en) * 2003-02-28 2009-07-08 石塚硝子株式会社 Antibacterial imparting glass composition and antibacterial polymer composite material using the same
US20040220534A1 (en) * 2003-04-29 2004-11-04 Martens Paul W. Medical device with antimicrobial layer
HUE045608T2 (en) * 2003-06-06 2020-01-28 Univ Texas Antimicrobial flush solutions
US7588033B2 (en) * 2003-06-18 2009-09-15 Breathe Technologies, Inc. Methods, systems and devices for improving ventilation in a lung area
US20050064020A1 (en) * 2003-08-14 2005-03-24 Schuette Robert L. Method for producing silver-containing antimicrobial fabric
EP1691614B1 (en) * 2003-12-04 2013-02-13 University Of Iowa Research Foundation Gallium inhibits biofilm formation
US20060014285A1 (en) * 2004-07-14 2006-01-19 Eldridge Gary R Methods and compositions for inhibiting biofilms
US7713539B2 (en) * 2004-07-19 2010-05-11 Boston Scientific Scimed, Inc. Medical devices containing radiation resistant block copolymer
DE102005042372B3 (en) * 2005-09-07 2007-01-18 Dräger Medical AG & Co. KG Artificial respiration and/or anesthetic device comprises hydrophilic polymer material surface that contains silver particle and mineral filler such as zeolite, silicon dioxide, titanium dioxide, alumina, and zircon oxide

Also Published As

Publication number Publication date
AU2004234001A1 (en) 2004-11-11
WO2004096330A2 (en) 2004-11-11
EP1617890A2 (en) 2006-01-25
US20060118122A1 (en) 2006-06-08
US20060118121A1 (en) 2006-06-08
DE602004027899D1 (en) 2010-08-12
JP2006525089A (en) 2006-11-09
CA2523857A1 (en) 2004-11-11
ATE472343T1 (en) 2010-07-15
AU2004234001B2 (en) 2010-08-12
US20040220534A1 (en) 2004-11-04
US20110067703A1 (en) 2011-03-24
WO2004096330A3 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
EP1617890B1 (en) Medical device with antimicrobial layer
JP2006525089A5 (en)
AU666573B2 (en) Suction catheter assemblies
US20120132212A1 (en) Endotracheal Tube with Multi-Mode Valve and Method of Using Same
US5638812A (en) Coated medico-surgical devices
CN101579550B (en) Artificial trachea cannula made of nano materials and preparation method thereof
CA1175727A (en) Multi-purpose tracheal tube
US8042544B2 (en) Prevention of ventilator associated pneumonia (VAP)
CN102905749B (en) There is the endotracheal intubation of one or more blockage element, blockage element and the method using blockage element
US20090255536A1 (en) Biofilm-Inhibiting Catheters and Tubings
US8408210B2 (en) Cuffless tracheal tube
US20090320834A1 (en) Dilator Loading Catheter
US20080078406A1 (en) Endotracheal tube and technique for using the same
US20090101152A1 (en) High surface area anti-microbial coated endotracheal tube
CN113350579B (en) Preparation method of anti-sputum-thrombus tracheal catheter loaded with hydrogel coating
CN102389616A (en) Antibacterial medical catheter coated with nano silver polymer cellular structure film
CN101554505A (en) Artificial trachea cannula with nanometre anti-microbial coating
US20100051035A1 (en) Low-pressure airway management device with active coating and method for patient care
CN201949389U (en) Antibacterial medical catheter with nano silver/polymer honeycomb films
US20230181852A1 (en) Endotracheal device for mechanical ventilation of a patient
CN201404565Y (en) Artificial trachea cannula with nano antibiotic material coating
CN201481948U (en) Artificial trachea cutting sleeve of anti-bacterial nano material coating layer
CN213252265U (en) Tracheal catheter with inner sleeve
Wang et al. Reduction of biofilm formation in rabbits by novel nano-silver/polyurethane coated endotracheal tube
Yarham et al. Ventilator-associated pneumonia and new airway technologies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051122

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070427

RIN1 Information on inventor provided before grant (corrected)

Inventor name: POTTER, ADIN M.

Inventor name: MARTENS, PAUL, W.

Inventor name: NIETO, ROBERT, L.

Inventor name: VIRAG, ROBERT

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004027899

Country of ref document: DE

Date of ref document: 20100812

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101001

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101102

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101011

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004027899

Country of ref document: DE

Effective date: 20110330

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20111101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111101

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20120209 AND 20120215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004027899

Country of ref document: DE

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004027899

Country of ref document: DE

Owner name: TYCO HEALTHCARE GROUP LP, US

Free format text: FORMER OWNER: MALLINCKRODT, INC., ST. LOUIS, US

Effective date: 20121002

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004027899

Country of ref document: DE

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

Effective date: 20121002

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004027899

Country of ref document: DE

Owner name: TYCO HEALTHCARE GROUP LP, MANSFIELD, US

Free format text: FORMER OWNER: MALLINCKRODT, INC., ST. LOUIS, MO., US

Effective date: 20121002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110429

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20130425

Year of fee payment: 10

Ref country code: DE

Payment date: 20130429

Year of fee payment: 10

Ref country code: GB

Payment date: 20130429

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20130506

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004027899

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140429

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004027899

Country of ref document: DE

Effective date: 20141101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20141231

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141101

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140429